Sterile API Manufacturing FAQs

The manufacture of sterile products is a complex activity that requires specific controls and measures to ensure the
quality of products manufactured.

The key principles of sterile product manufacturing include minimizing the risk of microbial, particulate, and endotoxin
contamination through appropriate facility and equipment design, qualified personnel, validated processes, and robust
monitoring systems. Quality Risk Management (QRM) and a documented Contamination Control Strategy (CCS) should
be applied throughout all operations.

Sterile APIs may be required for several types of pharmaceutical formulations, including:

• Injectables
• Inhalation products
• Implants
• Ophthalmic formulations

Active pharmaceutical ingredients (APIs) can be sterilized using several terminal sterilization methods, including dry
heat, moist heat, radiation, and other validated approaches. These methods are suitable when the API remains stable
under the required sterilization conditions and its molecular structure and impurity profile are not adversely affected.

Where terminal sterilization of the APIs is not feasible, sterilization by filtration followed by aseptic processing under
validated and controlled conditions is the option of choice.

When terminal sterilization is not feasible, sterile filtration followed by aseptic processing is the primary alternative. This specialized manufacturing approach ensures sterility by preventing contamination throughout the full production workflow and process rather than sterilizing the product at the final stage.

Aseptic processing is intended to prevent microbial, particulate, and endotoxin contamination. These controls help
ensure that the final API meets the sterility requirements necessary for use in sterile pharmaceutical formulations.

Sterility during aseptic processing is ensured through the application of Quality Risk Management (QRM) across all
stages of aseptic API production. This includes facility design, equipment qualification, process and controls design,
system implementation, and operational procedures. QRM provides a structured framework for identifying, assessing,
and controlling risks associated with sterile manufacturing. It supports consistent process performance and helps
ensure that the final API meets stringent sterility and quality requirements.

Aseptic capabilities should comply with the latest international regulatory requirements. The principal applicable
standards include:

• EU GMP Annex 1
• FDA Guidance for Industry: Sterile Drug Products. Current good Manufacturing Practices
• FDA guidelines (21 CFR Part 11)
• ISO standards, including ISO 13408 and ISO 14644
• PDA technical reports (TR), including TR 28 and TR 27
• USP <1116>

Together, these frameworks provide general guidance for the design and control of facilities, equipment, systems, and
procedures used in sterile product manufacturing, while reinforcing the application of Quality Risk Management (QRM)
principles.

Key requirements for premises and cleanroom design include the following:

• Controlled environments: Sterile manufacturing should be carried out in cleanrooms equipped with HEPA-filtered air to prevent microbial ingress. Appropriate airlocks and physical separation are required to maintain environmental control. Cleanrooms are classified into four grades (A–D), each with defined requirements.
• Closed systems and automation: Manufacturing systems should be designed to minimize human intervention. Barrier technologies such as RABS and isolators, together with automation, are recommended to reduce contamination risk.
• Equipment and utilities: Equipment should support effective cleaning and minimize contamination risk. Critical utilities, including water, gases, and steam, must be controlled, qualified, and periodically monitored.

Effective aseptic API processing control depends on the following elements:

• Personnel requirements: Only qualified and trained personnel should be permitted to enter cleanrooms. Gowning and hygiene requirements must be defined according to cleanroom grades. Continued training, qualifications, and routine monitoring should be supported by formal procedures for disqualification and retraining when needed.
• Environmental monitoring: Comprehensive monitoring of viable and non-viable particles is required, with alert and action limits established according to cleanroom grade. Routine trend analysis should be used to identify shifts that may affect process control. Cleanrooms should also be qualified and periodically requalified.
• Process monitoring: Robust validated procedures are required to demonstrate control of aseptic operations. These should include media fill runs designed to simulate worst case conditions. Periodic verification of the effectiveness of the controls in place for aseptic processing should include Aseptic Process Simulation (APS), also referred to as media fill. APS should be performed as part of the initial validation and periodically executed. Additional controls, such as sterilizing filter integrity testing and glove integrity monitoring, should also be included.
• Quality control (QC): Quality control should include expertise in microbiology, sterility assurance, and particulate control. Bioburden and endotoxin testing must be performed at defined stages. Sterility testing is the final verification step, but it should not be considered the sole assurance of sterility. Personnel, Environmental and process monitoring results and trend data should be reviewed as part of batch release.
• Adherence to the Pharmaceutical Quality system (PQS): the manufacturer’s PQS should encompass and address the specific requirements of sterile product manufacture and ensure that all activities are effectively controlled so that the risk of microbial, particulate and endotoxin/pyrogen contamination is minimized in sterile products.

Aseptic processing for sterile APIs is a highly controlled, complex activity that relies on purpose-built facilities, qualified personnel, validated processes, and robust monitoring to minimize risks of microbial, particulate, and endotoxin contamination. By leveraging validated aseptic processes, routine environmental and process monitoring, and
integrated microbiological expertise, a CDMO helps ensure consistent sterility assurance aligned with global regulatory expectations, while reducing the need for significant internal investment and accelerating timelines to clinical or commercial supply.